| A455 |
Foravirumab Biosimilar（Anti-Rabies virus GP Reference Antibody）
Featured
|
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III. |
|
| A456 |
Rafivirumab Biosimilar（Anti-Rabies virus GP Reference Antibody）
Featured
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails. |
|
| A457 |
Medella patent anti-RAMP-3 Biosimilar（Anti-RAMP3 Reference Antibody）
Featured
|
|
|
| A458 |
19G9 Biosimilar（Anti-RG1 Reference Antibody）
Featured
|
|
|
| A459 |
Elezanumab Biosimilar（Anti-RGMA Reference Antibody）
Featured
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism. |
|
| A460 |
DISC-0974 Biosimilar（Anti-RGMC / HFE2 Reference Antibody）
Featured
|
|
|
| A461 |
Roledumab Biosimilar（Anti-RHD / CD240d Reference Antibody）
Featured
|
Roledumab (LFB-R593) is a human IgG1-κ antibody targeting RHD/CD240D. Roledumab is expressed by YB2/0 rat hybridoma cells. |
|
| A462 |
LFB Anti-RhD Biosimilar（Anti-RHD / CD240d Reference Antibody）
Featured
|
|
|
| A463 |
Asclepius Technology patent anti-Robo1 CAR Biosimilar（Anti-ROBO1 Reference Antibody）
Featured
|
|
|
| A464 |
Zilovertamab Biosimilar(Anti-ROR1 Reference Antibody)
Featured
|
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling. |
|
| A465 |
Ozuriftamab Biosimilar(Anti-ROR2 Reference Antibody)
Featured
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC. |
|
| A466 |
Oncomed patent anti-RSPO1 Biosimilar(Anti-RSPO1 Reference Antibody )
Featured
|
|
|
| A467 |
Rosmantuzumab Biosimilar(Anti-RSPO3 Reference Antibody)
Featured
|
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors. |
|
| A468 |
Palivizumab Biosimilar(Anti-RSV-F Reference Antibody)
Featured
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice. |
|
| A469 |
Motavizumab Biosimilar(Anti-RSV-F Reference Antibody)
Featured
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research. |
|
| A470 |
Ozanezumab Biosimilar（Anti-RTN4 / NOGO Reference Antibody）
Featured
|
Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research. |
|
| A471 |
Atinumab Biosimilar（Anti-RTN4 / NOGO Reference Antibody）
Featured
|
Atinumab (6A3-IgG4) is an antibody. Teropavimab can be used for the research of spinal cord injury (SCI). |
|
| A472 |
NG-101 Biosimilar（Anti-RTN4 / NOGO Reference Antibody）
Featured
|
|
|
| A473 |
LK-1 Biosimilar(Anti-S100A4 Reference Antibody)
Featured
|
|
|
| A474 |
CDX-0158 Biosimilar(Anti-SCFR / c-Kit / CD117 Reference Antibody)
Featured
|
|
|
| A475 |
LOP628 Biosimilar(Anti-SCFR / c-Kit / CD117 Reference Antibody)
Featured
|
|
|
| A476 |
Wuhan U. patent anti-Nav1.9 Biosimilar（Anti-SCN11a / Nav1.9 Reference Antibody）
Featured
|
|
|
| A477 |
Duke anti-NAv1.7 Biosimilar（Anti-SCN9a / Nav1.7 Reference Antibody）
Featured
|
|
|
| A478 |
Pepinemab Biosimilar（Anti-SEMA4D / CD100 Reference Antibody ）
Featured
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D. |
|
| A479 |
Sanofi patent anti-PAI-1 Biosimilar（Anti-SERPINE1 Reference Antibody）
Featured
|
|
|
| A480 |
Abbv-011 Biosimilar（Anti-SEZ6 Reference Antibody）
Featured
|
|
|
| A481 |
Pritoxaximab Biosimilar(Anti-Shiga toxin (E.coli) Reference Antibody )
Featured
|
Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1. |
|
| A482 |
Setoxaximab Biosimilar(Anti-Shiga toxin (E.coli) Reference Antibody)
Featured
|
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1. |
|
| A483 |
MVT-5873 Biosimilar（Anti-Sialyl-Lewis A Reference Antibody）
Featured
|
|
|
| A484 |
AB-25E9 Biosimilar(Anti-Siglec-15 / CD33L3 Reference Antibody)
Featured
|
|
|
